Compare GSK plc (GSK) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard S&P 500 ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Vanguard S&P 500 ETF trades at $715.59 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 19.6× GSK plc's market cap, and GSK plc pays a 3.9% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard S&P 500 ETF for 55 Days on average.
| GSK | VOO | |
|---|---|---|
Market Cap | $91.88B | $1.80T |
Volume | 7,730,529 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $716.17 |
52-Week Low | $43.24 | $580.93 |
Typical Hold Time | 93 Days | 55 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
VOO trades at $711.37, down 0.43% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF's support and resistance levels are tightly clustered around the current price. Recent news highlights its role in dividend strategies and resilience during economic uncertainty, though short interest rose 46.9% in September 2026 (Defense World, 2026-10-03).
VOO offers broad S&P 500 exposure, benefiting from long-term market growth and diversification. Risks include market volatility, interest rate sensitivity, and potential earnings slowdowns, with S&P 500 profit growth expected to drop to 15% in 2027 (24/7 Wall Street, 2026-10-03). Its low-cost structure and historical performance support a steady outlook for buy-and-hold investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
